New Drug Breakthrough Offers Hope for Myelofibrosis Patients Struggling with Disease Control and Anemia Dilemma
AM730 · 1 SOURCES1 day ago6 MIN
Summary
A new generation JAK inhibitor has been included in the Hospital Authority's Drug Safety Net, offering myelofibrosis patients in Hong Kong a breakthrough treatment option that addresses both disease control and anemia management. The rare blood cancer, which affects approximately 100 new patients annually in Hong Kong with an average diagnosis age of 65, previously forced doctors to choose between controlling symptoms and worsening patients' life-threatening anemia. Clinical data shows about one-third of patients who previously required regular blood transfusions can become transfusion-independent after starting the new therapy.
Key Points
- Myelofibrosis is a rare blood cancer caused by acquired gene mutations in hematopoietic stem cells, leading to abnormal blood cell proliferation and fibrosis in the bone marrow that impairs normal blood cell production
- Approximately 40% of patients already have anemia at diagnosis, and without appropriate treatment, virtually all patients will eventually develop anemia; severe anemia reduces average survival to just 2.1 years
- Dr. Joe Chalet (喬夏利), Clinical Associate Professor in the Department of Medicine at the University of Hong Kong, explains that first-generation targeted drugs primarily controlled symptoms and splenomegaly but worsened anemia in most patients within the first six months
- The new JAK inhibitor works by inhibiting overactive JAK and ACVR1 proteins in bone marrow stem cells, suppressing inflammation and fibrosis while stimulating red blood cell production
- A patient in his 60s, identified as Mr. Zhang (張先生), who had been diagnosed with polycythemia vera more than 20 years ago before it evolved into myelofibrosis, showed significant improvement after three months on the new medication through the Drug Safety Net
Why It Matters
For Hong Kong's myelofibrosis patients, the inclusion of this new JAK inhibitor in the Drug Safety Net removes the impossible choice between managing their disease and enduring debilitating anemia, potentially extending survival and dramatically improving quality of life. With approximately 100 new cases diagnosed each year in the city, this treatment advancement offers tangible hope to patients who previously faced a grim prognosis, particularly those whose severe anemia left them housebound and unable to perform basic daily activities .
For Hong Kong's myelofibrosis patients, the inclusion of this new JAK inhibitor in the Drug Safety Net removes the impossible choice between managing their disease and enduring debilitating anemia, potentially extending survival and dramatically improving quality of life. With approximately 100 new cases diagnosed each year in the city, this treatment advancement offers tangible hope to patients who previously faced a grim prognosis, particularly those whose severe anemia left them housebound and unable to perform basic daily activities .